Association between low-density lipoprotein cholesterol level and all-cause mortality in idiopathic dilated cardiomyopathy patients: a single-institutional study
暂无分享,去创建一个
Mao Chen | Fangyang Huang | X. Pu | Kexin Jiang | Yutong Liu | Yanjiani Xu
[1] T. Minamino,et al. The Prognostic Value of B‐Type Natriuretic Peptide in Patients With Cardiac Sarcoidosis Without Heart Failure: Insights From ILLUMINATE‐CS , 2022, Journal of the American Heart Association.
[2] B. Nordestgaard,et al. Association between low density lipoprotein and all cause and cause specific mortality in Denmark: prospective cohort study , 2020, BMJ.
[3] T. Hohlfeld,et al. Lipid lowering therapy in cardiovascular disease: From myth to molecular reality. , 2020, Pharmacology & therapeutics.
[4] T. Strandberg,et al. Mortality and Cholesterol Metabolism in Subjects Aged 75 Years and Older: The Helsinki Businessmen Study , 2020, Journal of the American Geriatrics Society.
[5] Jiyan Chen,et al. The prognostic nutritional index might predict clinical outcomes in patients with idiopathic dilated cardiomyopathy. , 2019, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[6] M. Khan,et al. Association of baseline LDL-C with total and cardiovascular mortality in patients using proprotein convertase subtilisin-kexin type 9 inhibitors: A systematic review and meta-analysis. , 2019, Journal of clinical lipidology.
[7] M. Milošević,et al. CHOLESTEROL AND CHLORIDE IN ACUTE HEART FAILURE , 2019, Acta clinica Croatica.
[8] M. Schmitt,et al. Towards cardiac MRI based risk stratification in idiopathic dilated cardiomyopathy , 2018, Heart.
[9] Jennifer G. Robinson,et al. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis , 2018, JAMA.
[10] Lale Tokgözoğlu,et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel , 2017, European heart journal.
[11] J. Nunes. Statins and the cholesterol mortality paradox , 2017, Scottish medical journal.
[12] S. Cook,et al. The Diagnosis and Evaluation of Dilated Cardiomyopathy. , 2016, Journal of the American College of Cardiology.
[13] D. Diamond,et al. Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review , 2016, BMJ Open.
[14] U. Tietge. Hyperlipidemia and cardiovascular disease: inflammation, dyslipidemia, and atherosclerosis. , 2014, Current opinion in lipidology.
[15] Tevfik F Ismail,et al. The Prevalence and Prognostic Significance of Right Ventricular Systolic Dysfunction in Nonischemic Dilated Cardiomyopathy , 2013, Circulation.
[16] P. Reaven,et al. Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins , 2011, Cardiovascular diabetology.
[17] P. Schnohr,et al. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow‐up , 2011, Journal of internal medicine.
[18] M. Banach,et al. Statins and dilated cardiomyopathy: do we have enough data? , 2011, Expert opinion on investigational drugs.
[19] R. Berger,et al. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. , 2006, Journal of the American College of Cardiology.
[20] Richard B Devereux,et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[21] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[22] L. Tavazzi,et al. Coronary atherosclerosis in end-stage idiopathic dilated cardiomyopathy: an innocent bystander? , 2005, European heart journal.
[23] H. Gullu,et al. Decreased serum lipoprotein levels as a guide for clinical severity in patients with idiopathic dilated cardiomyopathy. , 2005, The Tohoku journal of experimental medicine.
[24] M. Hori,et al. Short-Term Statin Therapy Improves Cardiac Function and Symptoms in Patients With Idiopathic Dilated Cardiomyopathy , 2003, Circulation.
[25] E. Walker. Regression Modeling Strategies , 2003, Technometrics.
[26] Miriam Parker,et al. Idiopathic dilated cardiomyopathy: a common but mystifying cause of heart failure. , 2002, Cleveland Clinic journal of medicine.
[27] D. Hosmer,et al. A comparison of goodness-of-fit tests for the logistic regression model. , 1997, Statistics in medicine.